LX6171

LX6171 is an orally administered small molecule drug developed by Lexicon Pharmaceuticals as a selective inhibitor of SLC6A7, a high-affinity L-proline transporter found in the brain[3][4][5]. SLC6A7 is part of the gamma-aminobutyric acid (GABA) neurotransmitter transporter family and is expressed in regions involved in learning and memory[3][5]. The mechanism of action involves inhibition of this membrane transport protein at synaptic vesicles and presynaptic membranes within glutamatergic neurons[7]. Preclinical studies showed that both knockout mice lacking SLC6A7 and mice treated with LX6171 demonstrated improved performance on learning and memory tasks[5][7]. Clinical development included Phase 2a trials for cognitive impairment associated with disorders such as Alzheimer's disease, schizophrenia, vascular dementia, age-associated memory impairment (AAMI), attention deficit/hyperactivity disorder (ADHD), dementia, neurologic disorders, and schizoaffective disorders[1][2][4][7]. However, clinical trials did not show significant effects on attention or memory to justify further development for these indications; thus development was discontinued for cognition disorders[3][4].

Other names

914808-66-5UNII-61CSC3D89KUNII61CSC3D89KUNII 61CSC3D89KMethanone (3'-chloro(1,1'-biphenyl)-4-yl)(1-(2-pyrimidinyl)-4-piperidinyl)